Glaucoma is the condition that put medical marijuana on the map, and it is the one the evidence has walked away from most completely. The story starts in 1971, when Hepler and Frank reported in JAMA that smoking marijuana lowered the pressure inside the eye. That finding is real and has held up ever since. What it never did was turn into a treatment, because the drop lasts three to four hours and glaucoma damages the optic nerve around the clock. The American Glaucoma Society, the American Academy of Ophthalmology and the Canadian Ophthalmological Society all advise against cannabis for glaucoma.
So this page is a correction. Plenty of cannabis sites still list glaucoma as a qualifying condition and leave it there, as if the listing were the evidence. Our view is plain: an edible is a poor glaucoma treatment, and a worse one than the joint the 1970s studies used, because swallowed THC arrives late and on no fixed schedule. Nothing below is a reason to touch the drops your ophthalmologist prescribed.
Does a THC edible lower eye pressure?
Briefly, if at all. No trial has tested a dispensary edible. The closest is a six-patient Aberdeen pilot in which 5mg of THC under the tongue lowered pressure from 27.3 to 23.5 mm Hg at two hours, back to baseline after four. A 2026 meta-analysis found the oral-route drop was not statistically significant.
That pilot, Tomida 2006, is the one randomized glaucoma trial the National Academies found when it reviewed the field in 2017, and its conclusion (number 4-14, for anyone checking) reads like a shrug in committee language: limited evidence that cannabinoids are an ineffective treatment for eye pressure in glaucoma. The committee's reasoning was the duration. A treatment for glaucoma has to lower pressure continually, and every positive study showed benefit measured in hours.
The newest pooled number comes from Dhivagaran and colleagues in the October issue of the Canadian Journal of Ophthalmology. Across five studies and 99 patients, THC by any route cut peak pressure by about 15%. Intravenous THC did the heavy lifting at 33%. The oral route came in at 10.65%, with a confidence interval running from a 7.6% rise to a 28.9% drop, which is a statistician's way of saying nobody knows. And once the four studies with a control arm were compared against that control, the difference was no longer significant.
How long does the eye-pressure drop last?
Three to four hours, per the American Glaucoma Society's position statement, which means cannabis would have to be smoked every three hours to hold pressure down around the clock. The Academy of Ophthalmology's patient site puts it at eight to ten times a day, every day. Nobody runs a glaucoma regimen that way, and nobody would stay employable on one.
The AGS statement, written by Henry Jampel of Johns Hopkins and published in the Journal of Glaucoma in 2010, also lists what comes with the schedule: no driving, no heavy machinery, no working at full mental capacity, and for the smoked version, the lungs.
How many edibles would around-the-clock pressure control take?
Eight a day, on the AGS's every-three-hours arithmetic, including several between midnight and breakfast. At the 5mg the Aberdeen pilot used, that is 40mg of THC every day, which our dosing guide classes as very high (30mg and above). Each dose's main effects run 4 to 8 hours, so they stack, and the person on that schedule is never sober.
Now add the edible's particular problem. On our edible timing guide, onset runs 30 minutes to 2 hours after eating, with a typical delay of 30 to 90 minutes, and the peak comes 2 to 3 hours in. Edibles make the timing worse. A joint lowers pressure within the hour and lets the user see roughly when the effect began. A gummy eaten at midnight starts working at some point between 12:30 and 2 a.m., which means the next one has to go in before anyone knows whether the first one arrived. Hence the 3 a.m. gummy alarm: the regimen asks you to wake up, chew a dose and go back to sleep, then do it again at six.
Someone actually tried a version of this with capsules. Flach's 2002 report on the California Cannabis Therapeutic Research Program gave nine patients with end-stage glaucoma oral THC capsules or inhaled marijuana on top of their existing treatment. Pressure fell at first in all nine. The drops were not sustained, tolerance appeared, and all nine had stopped within one to nine months. The AGS cites exactly that result as its evidence that systemic THC is not a reasonable option for a disease that needs treatment for decades.
Why does lower blood pressure matter for the optic nerve?
Because the optic nerve needs blood flow, and systemic THC lowers blood pressure. The AGS statement argues that the drop in blood pressure can reduce or cancel whatever good the lower eye pressure does, which is why it will not endorse cannabis without a long-term trial that measures the health of the nerve itself.
Merritt's 1980 study of 18 glaucoma patients in Ophthalmology saw the sequence directly. Inhaled marijuana raised heart rate and lowered both blood pressure and eye pressure, with the eye pressure drop appearing to follow the blood pressure drop. Low standing blood pressure, a racing heart, palpitations and altered mental state turned up often enough that the authors ruled out routine use in the general glaucoma population. On the overnight schedule above, a THC dose that drops standing blood pressure at 3 a.m. is also a fall risk on the way to the bathroom.
Is a CBD product for glaucoma a good idea?
No, and the evidence points the wrong way. In the Aberdeen pilot, 20mg of CBD did not lower eye pressure at any point, and 40mg raised it from 23.2 to 25.9 mm Hg four hours after the dose. In 2018 work at Indiana University, CBD blocked the pressure drop THC produced in mice.
The mouse study, by Miller and Straiker's lab, found THC eye drops lowered pressure by about 28% for eight hours in male mice, and found CBD working against it through two opposing effects. Mice are not people, and the human pilot had six patients. That is still more evidence than exists for the "full-spectrum CBD for eye health" bottle, and all of it says the CBD is either doing nothing for the pressure or pushing it up. The Academy's 2021 patient page carries the headline that CBD can make glaucoma worse. A wellness product that can push up the number your eye doctor is trying to lower is a bad trade at any price.
What do eye doctors actually tell patients?
That cannabis is not a glaucoma treatment, and that the prescribed drops stay. The AGS concluded that marijuana's side effects, its short duration and the lack of evidence that it changes the course of glaucoma rule out recommending it in any form. The Academy of Ophthalmology and the Canadian Ophthalmological Society agree.
The gap between the clinic and the shop counter is wide. A University of Colorado team made mystery calls to Colorado medical dispensaries between October 2018 and March 2019: of the 203 they reached, 103 (51%) recommended marijuana products for glaucoma. Of 290 American Glaucoma Society members who answered a parallel survey, 22 (7.6%) had ever recommended it, most of them rarely. Among 231 of the team's own glaucoma patients, 2.6% had used it for their eyes. Leonard Seibold, who led the work, told the Academy's patient site that the likeliest effect is to "make you forget to take the eyedrops."
Glaucoma still sits on some state medical cannabis qualifying lists. The listing records a legislative decision and says nothing about the eye. Our guide to edibles for medical use covers how the card process works for the conditions where the evidence is better.
What if I already use cannabis for another condition?
Keep the glaucoma treatment and the monitoring exactly as they are, and tell the ophthalmologist about the cannabis. No study has shown that cannabis changes the course of glaucoma, so an edible taken for pain or sleep replaces none of the eye treatment, and the blood pressure point above is worth raising at the next visit.
Plenty of glaucoma patients are also chronic pain patients, and the case for cannabis there stands on its own evidence, set out on our chronic pain page. The risk the ophthalmologists describe is a patient who feels that the evening gummy is covering the eyes too and lets the drops slide. The damage glaucoma does to the optic nerve is permanent, which is why the monitoring visits matter. Do not stop prescribed drops on the strength of anything on this page or anywhere else.